Valley Brook Capital Group’s Biogen BIIB Stock Holding History

Valley Brook Capital Group’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-75	Closed	-$20K	–	142
2021 Q1	$20K	Sell	75 -150	-67%	-$40.5K	0.02%	306
2020 Q4	$55K	Buy	+225	New	+$58K	0.05%	187

Other funds holding BIIB

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Valley Brook Capital Group's BIIB Position: Q2 2021 in Review

Valley Brook Capital Group sold out of Biogen (BIIB) in Q2 2021, closing a stake of 75 shares — an estimated $20K sold.

Valley Brook Capital Group first reported a position in BIIB in Q4 2020 and held it in 2 quarters. The position peaked at $55K in Q4 2020. 1,106 funds tracked by Wall St. Rank hold BIIB as of Q2 2021.

Valley Brook Capital Group reported no remaining Biogen position as of Q2 2021 after selling out during the quarter.
Valley Brook Capital Group sold 75 Biogen shares in Q2 2021, an estimated $20K.
Valley Brook Capital Group first reported a position in Biogen in Q4 2020 and held it in 2 quarters.
Valley Brook Capital Group's Biogen position peaked at $55K in Q4 2020.
1,106 funds tracked by Wall St. Rank held Biogen as of Q2 2021.

Based on Valley Brook Capital Group's 13F filing for Q2 2021, filed 22 Jul 2021.